slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,939 EUR | -.--% | -.--% | -.--% |
24/06 | Sectorupdate: Gezondheidszorgaandelen stijgen maandagmiddag | MT |
24/06 | Sectorupdate: Gezondheidszorg | MT |
Vakgebied
Aantal werknemers: 62
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Monoclonal Antibodies
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Renfeng Guo
FOU | Founder | 53 | 01-12-07 |
Niels Riedemann
FOU | Founder | 51 | 01-12-07 |
Thomas Taapken
DFI | Director of Finance/CFO | 59 | 01-10-20 |
Camilla Chong
CTO | Chief Tech/Sci/R&D Officer | 58 | 01-07-23 |
Daniel Vetter
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-22 |
Maria Habel
CTO | Chief Tech/Sci/R&D Officer | 41 | 01-01-08 |
Bruce P. Burnett
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-20 |
Jan Medina
IRC | Investor Relations Contact | - | 22/02 |
Nicole Bertsch
HRO | Human Resources Officer | - | 01-03-21 |
Christian Schmid
LAW | General Counsel | - | 01-01-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Nicolas Fulpius
FOU | Founder | 51 | 01-12-07 |
Niels Riedemann
FOU | Founder | 51 | 01-12-07 |
Renfeng Guo
FOU | Founder | 53 | 01-12-07 |
Hege Hellstrom
BRD | Director/Board Member | 59 | 01-04-23 |
Richard Brudnick
BRD | Director/Board Member | 67 | 14-02-19 |
Anthony Gibney
BRD | Director/Board Member | 53 | 06-02-18 |
Mark Kubler
BRD | Director/Board Member | 49 | 01-01-15 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 58 883 272 | 54 560 784 ( 92,66 %) | 0 | 92,66 % |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. |
Biotechnology
|
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+20,17% | 127 mld. | |
+24,67% | 117 mld. | |
+25,44% | 27,67 mld. | |
-17,74% | 20,33 mld. | |
-15,17% | 16,79 mld. | |
-15,21% | 15,63 mld. | |
+11,91% | 14,84 mld. | |
-47,10% | 14,65 mld. | |
+54,50% | 14,43 mld. |
- Beurs
- Aandelen
- Koers IFRX
- Koers IF0
- Onderneming InflaRx N.V.